QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

January 9, 2018

Primary Completion Date

April 17, 2019

Study Completion Date

January 11, 2021

Conditions
Squamous Cell Carcinoma
Interventions
DRUG

Aldoxorubicin HCl

Aldoxorubicin hydrochloride

BIOLOGICAL

ETBX-011

Ad5 \[E1-, E2b-\]-CEA

BIOLOGICAL

ETBX-021

Ad5 \[E1-, E2b-\]-HER2

BIOLOGICAL

ETBX-051

Ad5 \[E1-, E2b-\]-Brachyury vaccine

BIOLOGICAL

ETBX-061

Ad5 \[E1-, E2b-\]-MUC1

BIOLOGICAL

GI-4000

Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins

BIOLOGICAL

GI-6207

Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins

BIOLOGICAL

GI-6301

Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins

BIOLOGICAL

haNK for infusion

NK-92 \[CD16.158V, ER IL-2\]

DRUG

Avelumab

Recombinant human anti-PD-L1 IgG1 monoclonal antibody

DRUG

bevacizumab

Recombinant human anti-VEGF IgG1 monoclonal

DRUG

Capecitabine

5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

DRUG

Cetuximab

Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.

DRUG

Cisplatin

cis-diamminedichloroplatinum(II)

DRUG

Cyclophosphamide

2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

DRUG

Fluorouracil

5-fluoro-2,4 (1H,3H)-pyrimidinedione

DRUG

Leucovorin

L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt

DRUG

nab-Paclitaxel

Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

DRUG

Necitumumab

Necitumumab is a recombinant human lgG1 monoclonal antibody.

PROCEDURE

SBRT

Stereotactic Body Radiation Therapy

BIOLOGICAL

N-803

Recombinant human superagonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RuSu/IgGI Fe complex1)

Trial Locations (1)

90245

Chan Soon-Shiong Institute for Medicine, El Segundo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ImmunityBio, Inc.

INDUSTRY